Society for Participatory Medicine

JANUARY 27, 2022

My mission of advocacy was widened and deepened upon my stage IV colorectal cancer diagnosis in 2014 when I shared my expertise with others fighting for scans and treatments. It builds trust to uncover unmet needs, provide solutions, and yield powerful, measurable results.

BioTech 107

BioTech Life Science Drug Development Patient Experience 107

Lloyd Price

DECEMBER 8, 2018

Craig Venter in 2014—at around $310 million, according to a Human Longevity regulatory filing obtained by Lagniappe Labs LLC, whose Prime Unicorn Index tracks valuations of privately held companies. But key facets of its business didn’t develop as planned, say people familiar with the company.

Pharmaceuticals 56

Pharmaceuticals Life Science BioTech Drug Development 56

Lloyd Price

JUNE 17, 2023

History of Livongo Livongo was founded in 2014 by Glen Tullman, who was the former CEO of Allscripts Healthcare Solutions. Here are some of the key milestones in Livongo's history: 2014: Livongo is founded by Glen Tullman. This could create a company that is able to develop and deliver personalized treatments to patients.

Digital Health 81

Digital Health Drug Development Telemedicine Telehealth 81

Lloyd Price

FEBRUARY 18, 2024

Understanding and Development (1990s-2000s): 1990s: Research delves into the GLP-1 receptor and its role in regulating metabolism. 2014: Liraglutide becomes the first GLP-1 RA approved for weight management. 1996: Studies suggest GLP-1's potential in managing type 2 diabetes and obesity.

Pharmaceuticals 60

Pharmaceuticals healthcare technology Leadership Drug Development 60

Healthcare IT Today

NOVEMBER 14, 2022

The new financing will be used to accelerate the organization’s rapid expansion, including growing its team of talent and expanding its product research and development function. Within Life Sciences, the firm focuses on MedTech, Diagnostics, and Opportunistic Drug Development. For more information, visit www.mtngp.com.

Life Science 95

Life Science HIPAA Drug Development healthcare technology 95

Insulin Nation

JUNE 4, 2019

SGLT2 Development and Method of Action. Ever since the first SGLT2 inhibitor (dapagliflozin) was approved by the EU in 2011 and the USA in 2014, it and another nine gliflozin drugs developed since then have been considered for (off-label) use in Type-1 diabetes, as well as in Type-2 diabetes for which they were first approved.

Drug Development 52

Drug Development 52